Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an update.
Medicenna Therapeutics Corp announced that its President and CEO, Dr. Fahar Merchant, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. This participation is significant for Medicenna as it provides an opportunity to showcase its innovative cancer immunotherapy developments to potential investors and stakeholders, potentially strengthening its market position and attracting new partnerships.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage cancer immunotherapy company specializing in the development of Superkines, which are novel, highly selective versions of IL-2, IL-4, and IL-13. Their products include MDNA11, a next-generation IL-2 Superkine, and bizaxofusp, an IL-4 Empowered Superkine with FastTrack and Orphan Drug status from the FDA and EMA. The company focuses on enhancing the treatment of immunologically ‘cold’ tumors through its BiSKITs and T-MASK programs.
Average Trading Volume: 34,064
Technical Sentiment Signal: Sell
Current Market Cap: C$72.85M
For an in-depth examination of MDNA stock, go to TipRanks’ Overview page.